2
项与 CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center) 相关的临床试验 / Not yet recruiting临床2期IIT Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
To determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
To determine the safety, efficacy and optimal cell dose of CAR 5/IL15-transduced CB-NK cells in patients with relapsed/refractory T-cell malignances, mantle cell lymphoma, and chronic lymphocytic leukemia. The efficacy and optimal dose will be identified for individual diseases.
100 项与 CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center) 相关的临床结果
100 项与 CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center) 相关的转化医学
100 项与 CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center) 相关的专利(医药)
100 项与 CAR.5/IL15-transduced CB-NK cells(M.D. Anderson Cancer Center) 相关的药物交易